Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelfinavir with temozolomide chemoradiotherapy for newly diagnosed glioblastoma
NL-OMON32210Phase 2Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nelfinavir in glioblastoma (GBM), sponsored by Maastricht University Medical Center+. Primary endpoints: Maximum tolerated dose of nelfinavir and Progression-free survival at 6 months. Started Apr 2009; status: recruiting.
02
Drugs
nelfinavir
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON32210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32210.